# A Preliminary Exploratory Cohort Study of COVID-19 mRNA Vaccine, Bivalent in Participants Aged 18 Years and Over in China

> **NCT05547256** · NA · UNKNOWN · sponsor: **AIM Vaccine Co., Ltd.** · enrollment: 54 (actual)

## Conditions studied

- SARS-CoV-2

## Interventions

- **BIOLOGICAL:** COVID-19 Variant (Omicron BA.5) mRNA Vaccine Low dose
- **BIOLOGICAL:** COVID-19 Variant (Omicron BA.5) mRNA Vaccine High dose
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05547256
- **Lead sponsor:** AIM Vaccine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-09-13
- **Primary completion:** 2022-12-05
- **Final completion:** 2024-03
- **Target enrollment:** 54 (ACTUAL)
- **Last updated:** 2023-02-14

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05547256

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05547256, "A Preliminary Exploratory Cohort Study of COVID-19 mRNA Vaccine, Bivalent in Participants Aged 18 Years and Over in China". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05547256. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*